NCT01123538

Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile

Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University Hospital of North Norway · Academic / Other
• Sex: Female
• Age: 45 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare combined postmenopausal hormone therapy natural progesterone to the one containing synthetic progestagen (i.e. chlormadinone acetate) at the blood transcriptome level.

Conditions

• Pharmacogenomics
• Systems Biology

Interventions

Type	Name	Description
DRUG	Progesterone	200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
DRUG	Chlormadinone acetate	5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)

Timeline

• Start date: 2008-12-01
• Primary completion: 2011-10-01
• Completion: 2012-10-01
• First posted: 2010-05-14
• Last updated: 2011-11-03

Locations

1 site across 1 country: Norway